NCT05109832

A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects

A Clinical Trial of the Absorption, Metabolism, and Excretion of [14C]IMP4297 in Chinese Adult Male Healthy Volunteers - A Human Material Balance and Biotransformation Study of [14C]IMP4297

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Impact Therapeutics, Inc. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of \[14C\]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects

Detailed description

Study design A Phase I, single-center, open-label, single arm study is designed to evaluate Absorption-Distribution-Metabolism-Excretion (ADME) of \[14C\]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects. 6-8 subjects are planned to be enrolled (at least 6 subjects complete the study)

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	14C-IMP4297	14C marked IMP4297

Timeline

• Start date: 2021-10-09
• Primary completion: 2021-12-06
• Completion: 2021-12-06
• First posted: 2021-11-05
• Last updated: 2025-09-16

Locations

1 site across 1 country: China